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Abstract
Primary rectal melanoma (PRM) is an uncommon malignancy whose
etiology remains unknown. Most patients present with rectal bleeding. Distant metastasis is commonly seen in the lung and liver. The
incidence rates for locoregional lymph node metastases on initial
presentation are almost 60%. Histology and immunochemistry are
useful and are the gold standard for diagnosis. The prognosis is very
poor due to the late presentation of patients. Optimum surgical treatment remains controversial. Abdominoperineal resection was considered traditionally but over time, has been found to have no survival benefit. Current literature and studies, therefore, recommend
wide local excision. The beneficial effects of chemotherapy versus
radiotherapy use are still debatable. Herein, we discuss a case of a
72-year-old Caucasian male with rectal bleeding found to have metastasized PRM.
Keywords: Primary rectal melanoma; Abdominoperineal resection;
Wide local excision

Introduction
Malignant melanoma is derived from the melanocytes and
commonly involves the skin. Aside from the skin, malignant
melanoma has been observed in the eyes, gastrointestinal
tract, head, and genital regions. The rectal region is the most
frequently affected part in gastrointestinal malignant melanoma. These mucosal tumors, unlike the skin, derive their
origin from the melanocytes in the non-keratinized squamous epithelium. Malignant melanoma of the rectum is an
extremely rare and very aggressive tumor [1]. It constitutes
only 0.5-4% of all anorectal malignancies and less than 1%
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of all melanomas. Most patients present usually in the fifth
or sixth decade of life [2, 3]. Some cases have reported an
association between rectal melanoma and Caucasian women;
however, due to inadequate population-based studies, this
remains inconclusive. The common presenting symptoms
are rectal bleeding, anal mass, and changes in bowel habits
[4]. PRM is lethal with a median survival of 24 months and
5-year survival of 10% [5].

Case Report
Investigations
A 72-year-old Caucasian male widower, with a past medical
history of an alcohol use disorder, presented to the emergency
department with a chief complaint of bleeding per rectum, anal
mass, and diarrhea for 11 months associated with anal pruritus and tenesmus. He denied any personal or family history of
cancer. Significant findings on physical examination included
a frail appearing elderly man with a distended abdomen, and
a soft, tender, friable mass protruding from the anus. The skin
was negative for any abnormal pigmentation or lesion. Significant laboratory findings included hemoglobin of 9.8 g/dL (reference range of 14 - 18 g/dL), platelet of 247 × 103/mm3 (150
- 440 × 103/mm3), mean corpuscular volume (MCV) of 75.7
fL (80 - 100 fL), albumin of 2.8 g/dL (3.1 - 4.5 g/dL), aspartate
transaminase/alanine transaminase (AST/ALT) of 28/21 U/L
(15 - 37/12 - 78 U/L), serum iron of 18 µg/dL (65 - 175 µg/dL),
ferritin of 17.9 ng/mL (22 - 322 ng/mL), and iron saturation of
6.2% (20-55%).
Diagnosis
The patient had a contrast-enhanced computed tomography
(CECT) of abdomen which showed numerous hepatic lesions,
with the largest measuring 2.4 cm in diameter, a large soft tissue mass at the anorectal junction with bilateral inguinal lymphadenopathy. Colonoscopy revealed a mass at the rectum
with friable mucosa, measuring about 3 cm (Fig. 1).
The result of the biopsy showed a malignant proliferation
of atypical pleomorphic cells with cherry-red macronuclei and
amphophilic cytoplasm containing pigment (Fig. 2). The neoplastic cells were positive for Sox10 and S100, confirming the
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Figure 1. Colonoscope retroflection in rectum revealing rectal mass (blue arrow).

diagnosis of malignant melanoma.
Treatment
Genetic testing was not done as the patient declined it. Abdominoperineal resection (APR) surgery with adjuvant chemotherapy was discussed with the patient but he opted for palliative
care with no intent for surgery or chemotherapy. The patient
died 5 months after diagnosis.

Discussion
PRM is a type of melanoma arising from melanocytes in
the rectal mucosa, more than 4 cm from the anal verge. This
constitutes the primary difference from anorectal melanoma,
which develops at or near the squamocolumnar junction [6].
PRM is a rare entity and not well documented in case reports
and literature reviews. Most cases are misdiagnosed as hemorrhoids, adenocarcinoma, polyp, and rectal ulcer. Diagnosis is
difficult for most clinicians due to its low incidence, non-specific symptoms, lack of melanin pigmentation, and histologic
similarities with other cancers like lymphoma and sarcoma [7].
Most cases reported a higher incidence of anal melanoma compared to PRM. Goldman et al [8] reported 49 cases of primary
anorectal melanoma among 24,323 patients with anorectal tumors in the total Swedish population between 1970 and 1984.
Of these 49 tumors, 45 (91%) were located at or near the anorectal junction, three at the anal verge (6%), and only one in
370

the rectum (3%) approximately 8 cm from the anal orifice [7].
Brady et al reported in another study [9] that summarized the
largest series of PRM in the literature at Memorial Sloan Kettering Cancer Center from 1929 to 1993. This retrospective review reported 85 patients who were considered to have primary anorectal melanoma. Seven patients (8%) had tumors that
were considered primary rectal malignant melanoma, while 78
patients (92%) had tumors that arose in the anal canal or the
anal margin. In our case report, our patient had PRM arising
5 cm from the anus with no other cutaneous lesion detected at
the time of diagnosis.
The cause of mucosal melanoma remains unidentified.
However, some reports have found the Caucasian race to be
a predisposing factor. The rate of mucosal melanoma remains
twice as higher in Caucasians compared to African Americans
[3]. Immunosuppression whether it is due to medications or
infections such as human immunodeficiency virus (HIV) is
associated with a high risk of melanoma. In a review of 619
patients who received cardiothoracic transplants, there was a
65-fold increased risk of cutaneous squamous cell carcinoma
and a threefold increase in the risk of malignant melanoma
[10]. Two susceptibility genes, CDKN2A and CDK4, have
been identified to be associated with melanoma. In familial
melanomas, a mutation in the CDKN2A gene, on the short arm
of chromosome 9, increases the risk of melanoma. This is a
tumor suppressor gene that encodes tumor suppressor proteins
p16 and p19. Mutations in this gene have been found in 25%
of familial melanomas [11, 12]. In addition, BRAF mutations
are frequently reported in nevi and malignant melanomas. The
frequency of BRAF mutation in mucosal melanomas is low
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Figure 2. (a) Submucosal melanoma (blue star) (H&E stain, × 200). (b) The proliferation of markedly atypical melanocytes with
prominent macronuclei (blue arrow) and cytoplasmic pigment (red arrow) (H&E stain, × 400). H&E: hematoxylin and eosin.

compared to that of primary cutaneous melanoma [13, 14].
In our patient, there was no family history of melanoma. Genetic testing was not done as he declined it. PRM has a high
tendency of spreading with the most common sites for metastases being inguinal lymph nodes, mesenteric lymph nodes,
hypogastric lymph nodes, para-aortic lymph nodes, liver, lung,
skin, and brain [1]. About 20% of recently diagnosed PRM
patients are positive for lymph node disease in the inguinal
region [15]. Distant metastases are identified in about 26-38%
of patients [1, 2].
Biopsy through colonoscopy or proctoscopy is the gold
standard to establish the diagnosis and staging of tumor extent.
CECT and magnetic resonance imaging aid the characterization and extent of the tumor. A positron emission tomography
scan can be used for lesions that are indeterminate on CECT.
Histology and immunochemistry aid in the confirmation of diagnosis. Useful markers commonly used include S100 protein,

Sox10, HMB 45, melan A, and microphthalmia transcription
factor (MITF) [16, 17]. Our patient’s biopsy was positive for
Sox10 and S100.
PRM is staged on a clinical basis, focusing on locoregional
and distant metastasis. Stage I is a local disease involving two
categories (stage IA with a depth of 0.75 mm, stage IB with
a depth 0.75 - 1.5 mm), stage II has increased thickness with
ulceration and has two substages (stage IIA with a depth of 1.5
- 4 mm, stage IIB > 4 mm), stage III involves regional lymph
nodes, and stage IV shows distant metastatic disease [2].
There is no consensus at this moment on which surgical approach is preferred in the treatment of malignant melanoma of the rectum. Traditionally, APR was recommended
due to its ability to control lymphatic spread predominantly
to mesenteric nodes [18]. Most recent studies however suggest a less aggressive wide local excision (WLE). Combining
radiation therapy with WLE has shown a decreased risk of
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local recurrence associated with this procedure. In a study
carried out at the University of Texas MD Anderson Cancer
Center, 54 patients who had WLE with radiotherapy between
1990 and 2008 had an excellent 5-year rate of local control
with no significant improvement in survival rate [19]. APR is
usually indicated for bulky tumors especially those with > 4
mm thickness, extensive tumors involving the anal sphincter
that is not amenable to local excision [20]. Some studies have
shown that APR is associated with increased mortality, especially in those with lymph node-positive disease. Nusrath
et al [21] conducted a study on 30 patients with anorectal
malignant melanoma, 15 had APR with a median survival of
13 months while five patients who had a WLE had a median
survival of about 36 months. This was attributed to larger
tumor size (3.5 cm) and positive nodal disease in the APR
group compared to WLE. A retrospective study by Pessaux
et al [18] showed no significant difference in survival between those that had APR versus WLE. This was attributed
to the small sample size. WLE however was recommended
for patients with easily achievable negative surgical margin
and APR, for those with extensive disease involving the anal
sphincter. In a meta-analysis study conducted by Smith et
al [22], no oncological benefit was found between APR and
WLE but recommended WLE with regular surveillance in
most patients because of increased morbidity associated with
APR. In some cases, surgical procedure is combined with adjuvant chemotherapy and radiotherapy in metastatic disease
to achieve a good response. Chemotherapeutic agents used
include cisplatin (CDDP), vinblastine (VB), dacarbazine
(DTIC), interferon B (IFN), and interleukins (ILs)-2-8. According to a retrospective study by Kim et al [23], the majority of patients who received combination therapy with CDDP/
DTIC/VB/IFN showed a major response with a median survival of 12.2 months, and only one with a complete response
had survival duration of about 43 months. Our patient had a
tumor size of 3 cm with distant metastasis to the liver, reflecting stage IV disease. The benefit of APR with chemotherapy
was discussed with him but he declined further treatment and
opted for palliative care.
Conclusion
The rarity of PRM and the limited number of patients who
present early have prevented definitive trials examining the
optimal treatment of curable rectal melanoma. Most patients
however die irrespective of the therapy chosen due to the rapid
tumor progression. Clinicians are therefore advised to carry
out an appropriate investigation of any rectal mass encountered in practice.
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and aggressive disease that carries a poor prognosis. To enlighten readers about treatment modalities for PRM.
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